Trials / Completed
CompletedNCT04989816
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab Deruxtecan | Trastuzumab deruxtecan (T-DXd) by intravenous infusion |
Timeline
- Start date
- 2021-08-20
- Primary completion
- 2023-06-16
- Completion
- 2024-02-28
- First posted
- 2021-08-04
- Last updated
- 2024-11-21
- Results posted
- 2024-11-21
Locations
24 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04989816. Inclusion in this directory is not an endorsement.